Misonix Incorporated
1938 New Highway
Farmingdale
New York
11735
United States
Tel: 631-694-9555
Fax: 631-694-9412
Website: http://www.misonix.com/
349 articles about Misonix Incorporated
-
Misonix to Present at the 40th Annual Canaccord Genuity Growth Conference
7/30/2020
Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 40 th Annual Canaccord Genuity Growth Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Wednesday, August
-
Misonix Reports Preliminary Fiscal 2020 Fourth Quarter Revenue of Approximately $13.5 Million
7/10/2020
Company Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational Synergies
-
Misonix to Present at the 17th Annual Craig Hallum Institutional Investor Conference On May 27
5/22/2020
Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 17th Annual Craig Hallum Institutional Investor Conference taking place on Wednesday, May 27, 2020. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix
-
Misonix Fiscal 2020 Third Quarter Revenue Rises to $17.9 Million
5/11/2020
Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported financial results for the fiscal 2020 third quarter ended March 31, 2020 as summarized below:
-
Misonix to Report Fiscal 2020 Third Quarter Financial Results and Host Conference Call and Webcast on May 11
5/6/2020
Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced that it will report its fiscal 2020 third quarter financial results after the market closes on Monday, May 11, 2020.
-
Misonix to Present at the 40th Annual Cowen Healthcare Conference on March 2
2/18/2020
FARMINGDALE, N.Y., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 40 th Annual Cowen Healthcare Conference taking place on Monday, March 2 nd at the Boston Marriott Copley Place hotel in Boston. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Mi
-
Misonix Announces Public Offering of Common Stock - Jan. 22, 2020
1/22/2020
Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced that it has commenced an underwritten public offering of its common stock.
-
Misonix Reports Preliminary Fiscal 2020 Second Quarter Revenue of Approximately $19.7 MillionReiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20%
1/13/2020
Misonix, Inc. announced preliminary unaudited fiscal 2020 second quarter revenue for the three months ended December 31, 2019 of approximately $19.7 million.
-
CryoLife and Misonix Enter Into Distribution Agreement for NeoPatch
12/19/2019
CryoLife, Inc. announced that it has entered into an agreement whereby Misonix will have exclusive US commercialization rights for CryoLife's NeoPatch product to treat a broad range of indications outside of cardiac and vascular surgery.
-
Misonix to Present at 38th Annual J.P. Morgan Healthcare Conference
12/17/2019
38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, at the Westin St. Francis Hotel in San Francisco, California.
-
Misonix Announces Results of New Large Real-World Studies That Further Prove the Clinical Effectiveness of TheraSkin
12/5/2019
Results of the studies were published in Wound Repair and Regeneration and International Wound Journal.
-
Misonix Fiscal 2020 First Quarter Record Quarterly Product Revenue Of $11.1 Million
11/7/2019
Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported financial results for the fiscal 2020 first quarter ended September 30, 2019 as summarized below:
-
Misonix to Report Fiscal 2020 First Quarter Financial Results and Host Conference Call and Webcast on November 7
10/28/2019
Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced that it will report its fiscal 2020 first quarter financial results after the market closes on Thursday, November 7, 2019.
-
New Study Shows Superior Healing Outcomes Associated with Ultrasonic Debridement
7/9/2018
Misonix, Inc. announced the results of a new Randomized Controlled Trial (RCT), which demonstrated superior healing outcomes associated with the use of ultrasonic debridement for lower extremity wounds.
-
Misonix to Report Fiscal 2018 Second Quarter Financial Results, Host Conference Call and Webcast on February 6
1/30/2018
The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the general public.
-
Misonix to Ring Nasdaq Closing Bell on January 10
1/10/2018
The ceremony is being held to celebrate the Company’s 25 years of listing on the Nasdaq.
-
Misonix Reports First Quarter Fiscal Year 2018 Financial Results
11/8/2017
Revenue for the first quarter of fiscal year 2018 was $7.3M, an increase of 18% compared with $6.2M in the previous year's first quarter.
-
Misonix Cites Significant Healthcare Cost Savings Using BoneScalpel in Bone Removal Procedures
10/26/2017
Misonix cited data that demonstrated the use of BoneScalpel can produce up to a 40% cost reduction in biologic grafting material spend in spinal fusion procedures.
-
Misonix Enters into $11M License, Royalty and Manufacturing Agreement
10/20/2017
The agreement calls for (i) upfront technology license fees and stocking orders of $5 million; (ii) minimum royalty payments from the sale of SonaStar products.
-
Misonix to Report First Quarter Fiscal Year 2018 Financial Results on Tuesday, November 7, 2017
10/18/2017
Conference call to be conducted same day at 4:30 pm ET.